Antibiotic-resistant Gram-negative Bacteremia in Pediatric Oncology Patients-Risk Factors and Outcomes

被引:61
|
作者
Haeusler, Gabrielle M. [1 ,2 ]
Mechinaud, Francoise [2 ]
Daley, Andrew J. [3 ,7 ]
Starr, Mike [1 ]
Shann, Frank [4 ,7 ]
Connell, Thomas G. [1 ,5 ]
Bryant, Penelope A. [1 ]
Donath, Susan [5 ,6 ,7 ]
Curtis, Nigel [1 ,5 ,7 ]
机构
[1] Univ Melbourne, Royal Childrens Hosp Melbourne, Dept Gen Med, Infect Dis Unit, Parkville, Vic 3052, Australia
[2] Univ Melbourne, Royal Childrens Hosp Melbourne, Childrens Canc Ctr, Parkville, Vic 3052, Australia
[3] Univ Melbourne, Royal Childrens Hosp Melbourne, Dept Microbiol, Parkville, Vic 3052, Australia
[4] Univ Melbourne, Royal Childrens Hosp Melbourne, Intens Care Unit, Parkville, Vic 3052, Australia
[5] Univ Melbourne, Royal Childrens Hosp Melbourne, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia
[6] Univ Melbourne, Royal Childrens Hosp Melbourne, Clin Epidemiol & Biostat Unit, Parkville, Vic 3052, Australia
[7] Univ Melbourne, Royal Childrens Hosp Melbourne, Dept Paediat, Parkville, Vic 3052, Australia
关键词
antibiotic resistance; immunosuppressed; febrile neutropenia; child; NEUTROPENIC CANCER-PATIENTS; CELL TRANSPLANT RECIPIENTS; ANTIMICROBIAL RESISTANCE; BACILLI; CHILDREN; EXPERIENCE; LEUKEMIA; THERAPY; TRENDS;
D O I
10.1097/INF.0b013e31828aebc8
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Infection with antibiotic-resistant (AR) Gram-negative (GN) bacteria is associated with increased morbidity and mortality. The aim of this study was to determine risk factors and outcomes associated with GN bacteremia with acquired resistance to antibiotics used in the empiric treatment of febrile neutropenia in pediatric oncology patients at our institution. Methods: All episodes of GN bacteremia in oncology patients at the Royal Children's Hospital Melbourne, from 2003 to 2010 were retrospectively reviewed. Information regarding age, diagnosis, phase of treatment, inpatient status, previous AR GN infection, treatment with inotropes or ventilatory support, admission to intensive care unit, and hospital and intensive care unit length of stay were obtained from electronic records. Results: A total of 280 episodes of GN bacteremia in 210 patients were identified. Of these, 42 episodes in 35 patients were caused by an AR GN organism. Factors independently associated with AR GN bacteremia were high-intensity chemotherapy (odds ratio 3.7, 95% confidence interval: 1.2-11.4), hospital-acquired bacteremia (odds ratio 4.3, 95% confidence interval: 2.0-9.6) and isolation of AR GN bacteria from any site within the preceding 12 months (odds ratio 9.9, 95% confidence interval: 3.8-25.5). Episodes of AR GN bacteremia were associated with longer median hospital length of stay (23.5 days versus 14.0 days; P = 0.0007), longer median intensive care unit length of stay (3.8 days versus 1.6 days; P = 0.02) and a higher rate of invasive ventilation (15% versus 5.2%; P = 0.03). No significant difference in infection-related or all-cause mortality between the 2 groups was identified. Conclusions: In pediatric oncology patients, AR GN bacteremia is associated with an increased rate of adverse outcomes and is more likely in patients who have received high-intensity chemotherapy, have been in hospital beyond 48 hours and who have had previous AR GN infection or colonization.
引用
收藏
页码:723 / 726
页数:4
相关论文
共 50 条
  • [21] Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes
    Gudiol, C.
    Tubau, F.
    Calatayud, L.
    Garcia-Vidal, C.
    Cisnal, M.
    Sanchez-Ortega, I.
    Duarte, R.
    Calvo, M.
    Carratala, J.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (03) : 657 - 663
  • [22] Emergence and Control of Antibiotic-resistant Gram-negative Bacilli in Older Adults
    Dror Marchaim
    David E. Katz
    L. Silvia Munoz-Price
    Current Translational Geriatrics and Experimental Gerontology Reports, 2013, 2 (3): : 113 - 124
  • [23] Risk factors for piperacillin/tazobactam-resistant Gram-negative infection in hematology/oncology patients with febrile neutropenia
    Marini, Bernard L.
    Hough, Shannon M.
    Gregg, Kevin S.
    Abu-Seir, Haya
    Nagel, Jerod L.
    SUPPORTIVE CARE IN CANCER, 2015, 23 (08) : 2287 - 2295
  • [24] What are the risk factors for antibiotic resistant Gram-negative bacteraemia in children with cancer?
    Haeusler, Gabrielle M.
    Levene, Ilana
    ARCHIVES OF DISEASE IN CHILDHOOD, 2015, 100 (09) : 895 - 898
  • [25] Pediatric Gram-negative bloodstream infections: epidemiology, antibiotic resistance, clinical outcomes and factors affecting mortality, a single center retrospective study
    Yilmaz, Seyhan
    Akkoc, Gulsen
    Tuncay, Sevgi Aslan
    Parlak, Burcu
    Erdemli, Pinar Canizli
    Isik, Aylin Dizi
    Ergenc, Zeynep
    Ilki, Arzu
    Toprak, Nurver Ulger
    Ergan, Bilgehan
    Demir, Sevliya Ocal
    Kepenekli, Eda
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2025, 19 (02): : 238 - 247
  • [26] Clinical aspects of severe infections caused by antibiotic-resistant Gram-negative bacteria
    Sinko Janos
    ORVOSI HETILAP, 2017, 158 (39) : 1528 - 1534
  • [27] Antibiotic-resistant clones in Gram-negative pathogens: presence of global clones in Korea
    Ko, Kwan Soo
    JOURNAL OF MICROBIOLOGY, 2019, 57 (03) : 195 - 202
  • [28] Antibiotic-resistant gram-negative bacteria in birds from the Brazilian Atlantic Forest
    Nascimento, AMA
    Cursino, L
    Gonçalves-Dornelas, H
    Reis, A
    Chartone-Souza, E
    Marini, MA
    CONDOR, 2003, 105 (02): : 358 - 361
  • [29] Impact of a hospital-wide programme of heterogeneous antibiotic use on the development of antibiotic-resistant Gram-negative bacteria
    Takesue, Y.
    Nakajima, K.
    Ichiki, K.
    Ishihara, M.
    Wada, Y.
    Takahashi, Y.
    Tsuchida, T.
    Ikeuchi, H.
    JOURNAL OF HOSPITAL INFECTION, 2010, 75 (01) : 28 - 32
  • [30] Antibiotic strategies and clinical outcomes for patients with carbapenem-resistant Gram-negative bacterial bloodstream infection
    Qu, Junyan
    Feng, Chunlu
    Li, Huan
    Lv, Xiaoju
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2021, 57 (03)